



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/060765

(22) International Filing Date:
24 November 2021 (24.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/117,861 24 November 2020 (24.11.2020) US
63/231,626 10 August 2021 (10.08.2021) US

(71) Applicant: **SENTI BIOSCIENCES, INC.** [US/US]; 2
Corporate Drive, First Floor, South San Francisco, California
94080 (US).

(72) Inventors: **GARRISON, Brian Scott**; c/o Senti Bio-
sciences, Inc., 2 Corporate Drive, First Floor, South San
Francisco, California 94080 (US). **GONZALEZ-JUNCA,**
Alba; c/o Senti Biosciences, Inc., 2 Corporate Drive, First
Floor, South San Francisco, California 94080 (US). **LEE,**
Gary; c/o Senti Biosciences, Inc., 2 Corporate Drive,
First Floor, South San Francisco, California 94080 (US).
ROGUEV, Assen Boyanov; c/o Senti Biosciences, Inc., 2

Corporate Drive, First Floor, South San Francisco, California
94080 (US).

(74) Agent: **NEWMAN, Zachary R.** et al.; Goodwin Procter
LLP, 100 Northern Avenue, IP Docketing Dept./7th Fl,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CHIMERIC RECEPTORS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are solid tumor antigen targets for
chimeric receptors and chimeric inhibitory receptors, and methods of
using the same, such as for the treatment of cancer.




FIG. 28

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*